Minimal Residual Disease Testing: Global Markets and Technologies

Report Code: PHM275A

Publish Date: Aug 2023

Publisher: BCC Publishing

Category: Pharmaceuticals

Download Report Overview

Single User License: $5500

Member Price: FREE

Use code SUMMER at checkout for 50% OFF

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for minimal residual disease testing is estimated to increase from $2.2 billion in 2023 to reach $4.3 billion by 2028, at a compound annual growth rate (CAGR) of 14.3% from 2023 through 2028.

Report Includes

  • 44 data tables and 45 additional tables
  • An up-to-date overview and in-depth analysis of the global markets for minimal residual disease (MRD) testing
  • Analyses of the global market trends, historical market revenue (sales figures) data from 2021-2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
  • Estimation of the actual market size and revenue forecast for global minimal residual disease testing market in USD million values, and corresponding market share analysis based on technology, application, and region
  • In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of COVID-19 on the progress of this market
  • Detailed description of specific somatic or germline mutations that serve as precise markers to diagnose cancer during ongoing investigations
  • Coverage of major cancers such as leukemia, lymphoma, and multiple myeloma, and discussion on how MRD level monitoring enables more precise evaluations, thereby identifying the amount of risk or enabling early prevention of future relapse
  • Discussion of the importance of ESG in global minimal residual disease testing market, consumer attitudes, risks and opportunity assessment, future trends, and ESG followed practices within the industry
  • A look at the major vendors in minimal residual disease testing market, and analyze the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities
  • Identification of the major stakeholders and analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
  • Detailed company profiles of the leading market players, including Adaptive Biotechnologies, Invitae Corp., Guardant Health, Natera Inc., NeoGenomics Inc., Exact Sciences Corp., and Quest Diagnostics

Report Scope

The report’s scope includes an overview of the global market on minimal residual disease testing and an analysis of global market trends, using 2022 as the base year and forecasting 2023 through 2028 with a compound annual growth rate (CAGR) projection.

The report analyzes leading and emerging technologies, applications, end-user, and product pipeline details for minimal residual disease testing. Profiles of leading market players, their specific products, financial information, and recent market activities are provided. This report also assesses companies’ mergers and acquisitions and funding activities and their impact in the face of the competitive environment. The report details the minimal residual disease testing market based on technology, application, and end user. The market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others based on technology.

The market is categorized as hematological malignancies [leukemia, lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma), myeloma], solid tumors, and others based on application. The report also considers the impact of the Covid-19 pandemic on this market. Regional analysis includes North America (U.S., Canada, and Mexico), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the World (South America and the Middle East and Africa).

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $1.7 billion
Market size forecast $4.3 billion
Growth rate CAGR of 14.3% from 2023 to 2028
Units considered $ Millions
Segments covered By Technology, Application, and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Market Drivers
  • Rising Incidence of Cancer and Hematological Malignancies Globally
  • Advancements in Next Generation Sequencing (NGS) Technology
  • Increasing Awareness Regarding Early Cancer Detection
Companies studied
ADAPTIVE BIOTECHNOLOGIES CORP.AMGEN INC.
ASTRAZENECABIO-RAD LABORATORIES INC.
CERGENTIS B.V.EXACT SCIENCES CORP.
GUARDANT HEALTH INC.GRAIL
INVITAEINVIVOSCRIBE INC.
NATERA INC.NEOGENOMICS INC.
QIAGENSYSMEX CORP.
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Frequently Asked Questions (FAQs)

The global minimal residual disease testing market was valued at $2.2 billion in 2023 and will reach $4.3 billion by 2028, at an estimated CAGR of 14.3%.
  • Rising incidence of cancer and hematological malignancies globally.
  • Advancements in Next Generation Sequencing (NGS) technology.
  • Growing awareness regarding early cancer detection.
The minimal residual disease testing market is segmented based on technology, application, and region.
Hematological malignancies segment will dominate the market by the end of 2028.
North America holds the highest share of the market.
Key companies in the market includes Exact Sciences Corp., Grail LLC, Natera, Inc., Invitae Corp., Qiagen N.V., and Quest Diagnostics among others.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Minimal Residual Disease Testing: Global Markets and Technologies152Free
Chapter- 1: Introduction6Free
Chapter- 2: Summary and Highlights3Free
Chapter- 3: Market Overview5Free
Chapter- 4: Market Dynamics9Free
Chapter- 5: Global Minimal Residual Disease Testing Market by Technology8Free
Chapter- 6: Global Minimal Residual Disease Testing Market by Application19Free
Chapter- 7: Global Minimal Residual Disease Testing Market by Region21Free
Chapter- 8: ESG Developments8Free
Chapter- 9: Emerging Technologies and Developments1Free
Chapter- 10: M&A Analysis2Free
Chapter- 11: Competitive Intelligence12Free
Chapter- 12: Company Profiles58Free

Related Reports

Next-Generation Cancer Diagnostics: Technologies and Global Markets

Published - Jun 2023 | Publisher - Kottapenta Sai Ratna Bramara Kalyani | Code - BIO081D

The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.

Monoclonal Antibodies for Oncology: Global Markets

Published - Jul 2022 | Publisher - BCC Publishing | Code - PHM261A

The global market for monoclonal antibodies in oncology is estimated to grow from $76.2 billion in 2022 to more than $138.1 billion by 2027, with a compound annual growth rate (CAGR) of 12.6% during the forecast period of 2022-2027.

Biological Therapies for Cancer: Technologies and Global Markets

Published - Oct 2021 | Publisher - BCC Publishing | Code - BIO048D

The global cancer biologics market should reach $143.0 billion by 2026 from $77.5 billion in 2021 at a compound annual growth rate (CAGR) of 13.0% for the forecast period of 2021 to 2026.

Global Oncology Pharmaceuticals Market

Published - Oct 2021 | Publisher - BCC Publishing | Code - PHM256A

The global market for oncology pharmaceuticals should grow from $177.4 billion in 2021 to $313.7 billion by 2026, at compound annual growth rate (CAGR) of 12.1% for the period of 2021-2026.

Recent Reports

Global Markets for Drug-Device Combinations

Published - Aug 2024 | Publisher - BCC Publishing | Code - PHM045F

The global market for drug-device combinations is expected to grow from $129.4 billion in 2024 and is projected to reach $199.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 9.1% during the forecast period of 2024 to 2029.

Drugs and Diagnostics for Hematological Disorders: Global Markets

Published - Aug 2024 | Publisher - BCC Publishing | Code - PHM116C

The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.

Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets

Published - Apr 2024 | Publisher - BCC Publishing | Code - PHM046D

The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.

Global Markets and Technologies for Advanced Drug Delivery Systems

Published - Mar 2024 | Publisher - BCC Publishing | Code - PHM006N

The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM113C

The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.

Top Trending Reports

Sensors: Technologies and Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - IAS006P

The global market for sensors is estimated to increase from $179.7 billion in 2023 to reach $300.5 billion by 2029, at a compound annual growth rate (CAGR) of 8.9% from 2024 through 2029.

Hydrogen Storage: Materials, Technologies and Global Markets

Published - Jul 2024 | Publisher - BCC Publishing | Code - EGY146C

The global market for hydrogen storage materials and technologies is expected to grow from $5.3 billion in 2023 to $7.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.6% from 2023 through 2028.

Solid State Batteries: Global Markets

Published - Jul 2024 | Publisher - BCC Publishing | Code - FCB053B

The global market for solid state batteries is estimated to increase from $274.0 million in 2023 to reach $1.7 billion by 2029, at a compound annual growth rate (CAGR) of 36.7% from 2024 through 2029.

Global Market for Cell and Gene Therapy

Published - Apr 2024 | Publisher - BCC Publishing | Code - BIO225B

The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028. 

Life Science Tools and Reagents: Global Markets

Published - Jul 2024 | Publisher - BCC Publishing | Code - BIO083E

The global market for life science tools and reagents, including COVID-19 diagnostics was valued at $59.4 billion in 2023. This market is expected to grow from $53.2 billion in 2024 to reach $66.5 billion by the end of 2029, at a CAGR of 4.6% during the forecast period of 2024-2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Minimal Residual Disease Testing: Global Markets and Technologies
Sample Report